We recently published a list of Top Dividend Stocks to Buy in 2024 According to Billionaire Paul Tudor Jones. Since Amgen Inc (NASDAQ:AMGN) ranks 6th in the list, it deserves a deeper look.
Billionaire Paul Tudor Jones recently made headlines after he participated in the Robin Hood foundation’s fundraising event dressed as Neo from the movie “The Matrix.” The event raised $68.5 million. The billionaire, who founded Tudor Investment Corporation in 1980, couldn’t help himself but talk about investing during the event, and highlighted the importance of “Warren Buffett-style compounding.”
“Somewhere, somehow the multiplicative power of compound put you in this seat,” Tudor Jones said.
During an interview last year, the billionaire had predicted that a recession was expected to start in the first quarter of 2024. He said at the time that the US was in its “weakest position” since World War II. However, the market rally fueled by AI proved the prediction wrong. Earlier this year, Jones said in another interview that the financial markets represent people’s ideas and what they make of the economic situation. Paul Tudor Jones said that there’s a chance the stock market would be “here or lower” in the next five to ten years. However, the billionaire also said it’s possible that the markets would go higher from here if the next President of the US devises a better “policy response” next year.
READ NEXT: Billionaire Cooperman’s Top Dividend Picks and Analysts Are Upgrading These AI Stocks
He’s been vocal about AI lately and sharing his thoughts about the impact of technology on our society. He thinks AI could be the “knight on the horse that rides and saves us.”
But AI-related threats worry Paul Tudor Jones. In an interview in January he referred to a survey where close to 3,000 AI experts were asked whether they believe AI would end humanity. According to Jones, a whopping 58% of the experts said yes. The billionaire said US policymakers will have to decide how to tackle this problem. Jones believes AI is growing at an “unbridled pace” since there’s so much money to be made in the domain but the biggest problem for policymakers would be to balance the benefits and threats of AI to make it sustainable.
For this article we scanned billionaire Paul Tudor Jones’ Q1 portfolio and chose his top dividend stock picks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Amgen Inc (NASDAQ:AMGN)
Billionaire Paul Tudor Jones Q1’2024 Stake: $46,742,208
Biopharmaceutical company Amgen Inc (NASDAQ:AMGN) is a new stock pick of billionaire Paul Tudor Jones as his investment fund bought 164,400 shares of Amgen Inc (NASDAQ:AMGN) for about $47 million. Analysts believe Amgen Inc (NASDAQ:AMGN) could become a promising weight loss stock, as Amgen Inc’s (NASDAQ:AMGN) management in latest earnings call talked in detail about the phase 2 trial of the drug. Here’s what Amgen Inc (NASDAQ:AMGN) said:
“All arms remain active, patient dropout has not been an issue, and we’re fully on track for top line 52-week data from this 11-arm Phase II study in late 2024. We’re seeing a differentiated profile of MariTide and are confident that it will address important unmet medical needs, obesity, obesity-related conditions and diabetes. We look forward to completing the ongoing Phase II study and working with regulators to move rapidly to the broad Phase III program. Later this year, we plan to initiate an additional dedicated Phase II trial investigating MariTide for the treatment of diabetes in patients with and without obesity.
This new trial is not a gating step for our Phase III program in patients with obesity. Informed by dose and schedule insights from the ongoing Phase II obesity study, the dedicated Phase II study in diabetes conforms to regulatory requirements for Phase III and is the next step towards a diabetes indication for MariTide. In terms of patient experience, we expect to deliver MariTide in a convenient, handheld, patient-friendly auto-injector device with a monthly or even less frequent single-injection administration, assuming eventual approval. [read the full earrings call transcript here]”
As of the end of the first quarter of 2024, 63 hedge funds tracked by Insider Monkey reported owning stakes in Amgen Inc (NASDAQ:AMGN). The biggest stakeholder of Amgen Inc (NASDAQ:AMGN) during this period was David Kroin’s Deep Track Capital which owns a $156 million stake in Amgen Inc (NASDAQ:AMGN).
Based on 2025 EPS estimate of $20.44 for Amgen Inc (NASDAQ:AMGN), the stock’s forward PE ratio is around 15, which is less than the industry average of 19. Analysts believe the stock is undervalued as Amgen Inc (NASDAQ:AMGN) is poised to grow earnings and revenue thanks to its weight loss drug and other catalysts including lung cancer treatment. William Blair recently upgraded the stock following Amgen Inc’s (NASDAQ:AMGN) bullish remarks on weight loss drug MariTide. AMGN is one of the top dividend stocks to buy in 2024.
Overall, Amgen Inc (NASDAQ:AMGN) ranks 6th in Insider Monkey’s list of Top Dividend Stocks to Buy in 2024 According to Billionaire Paul Tudor Jones. You can visit Top Dividend Stocks to Buy in 2024 According to Billionaire Paul Tudor Jones to see other stock picks of Billionaire Paul Tudor Jones. While we acknowledge the potential of Amgen Inc (NASDAQ:AMGN), our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than Amgen Inc (NASDAQ:AMGN) but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: Michael Burry Is Selling These Stocks and Jim Cramer is Recommending These Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
